The Role of Celecoxib for Treatment of Refractory Nocturia Caused by Benign Prostatic Hyperplasia

Abstract

Objective: Nocturia is a well-recognized symptom in patient with benign prostatic hyperplasia ( BPH), which is commonly treated by alpha- blocker and/ or 5 alpha - reductase inhibitors. However, the effectiveness of these drugs for nocturia has been reported to be only 25%- 39%. The aim of this study was to investigate the efficacy of celecoxib, a cyclooxygenase -2 inhibitor, in the treatment of patient with BPH complaing of nocturia.Patients and methods: A prospective study of 50 men with signs tract symptoms and BPH of refractory nocturia to alpha- blocker and/ or 5 alpha reductase inhibitor more than two episodes of nocturia per night were involved for nocturia. Although these patients had received standard drug therapy for more than one month , they had still three or more episodes of nocturia. The patients took a single dose of 100 mg of celecoxib at night prior to sleep. and 2 week after the initiation of this therapy, the effects of this treatment were assessed by frequency chart and a questionnaire.Results: In the questionnaire ,32 of 50 patients (64%) had an excellent response with celecoxib treatment than previous treatments, 14 of 50 patients (24%) had an improvement with celecoxib treatment than previous treatments, 4 of 50 patients (8%) had no response with celecoxib treatment, Nocturnal frequency showed a statistically significant reduction from, baseline after two weeks treatment with celecoxib (P < 0.01), International Prostate Symptom Score( IPSS) showed a statistically significant reduction from baseline after two weeks treatment with celecoxib (P < 0.01), peak flow rate showed a statistically no response from baseline after two weeks treatment with celecoxib (P < 0.05).Conclusion: Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia. The results suggest a novel treatment option for this common condition.